A new combination involving the pancreatic cancer drug daraxonrasib produced confirmed tumor responses in 60.7% of 61 patients with metastatic disease, researchers reported at a European cancer conference on November 20, 2026. Some patients had no detectable tumors on the scans used to evaluate their response. The figures have attracted attention because advanced pancreatic cancer remains exceptionally difficult to treat.
Does this mean a major new first-line treatment is ready for patients? The early results are promising, but the crucial test—whether adding the drug improves outcomes compared with chemotherapy alone—is still under way.
What did the daraxonrasib trial find?
The findings come from RMC-GI-102, an open-label phase 1/2 study. Its first-line metastatic pancreatic adenocarcinoma cohort received oral daraxonrasib together with the chemotherapy drugs gemcitabine and nab-paclitaxel.
The analysis presented at the EORTC-NCI-AACR Symposium in Barcelona included 61 patients, using data collected through September 28, 2026. Median follow-up was 18.3 months.
The reported results were:
- 60.7% confirmed objective response rate: tumors measurably shrank or were no longer detectable in approximately six out of ten participants.
- 8.2% complete response rate: scans showed no detectable target disease in about five patients. A complete response does not establish that the cancer has been permanently cured.
- 90.2% disease control rate: the proportion whose disease either shrank or remained stable.
- 12.8 months median progression-free survival: the point at which half the participants had experienced disease progression or died, while the other half had not.
- 76.6% estimated overall survival at 12 months: an estimate of the proportion alive a year after treatment began, not the median overall survival.
These are outcomes measured within the treated group. They are not a head-to-head comparison with chemotherapy alone, which is the main limitation when interpreting the headlines.
Why might this treatment work?
Most pancreatic adenocarcinomas involve changes in the RAS signaling pathway, frequently involving KRAS. This pathway normally helps regulate cell growth; cancer-associated alterations can leave growth signals persistently active.
Daraxonrasib, marketed as Rasonque, is an oral drug designed to inhibit active RAS proteins. In this study, investigators tested whether combining that targeted approach with established chemotherapy could improve the initial treatment of cancer that has already spread beyond the pancreas.
The reported combination used 200 mg of daraxonrasib daily alongside scheduled intravenous chemotherapy. That is a clinical-trial regimen, distinct from the FDA-approved labeled dose for the drug’s existing indication. Trial dosing should not be interpreted as a treatment instruction.
How strong is the evidence?
The response rate is an important signal, particularly for a disease where tumors often resist therapy. But this was a small, non-randomized early-phase cohort. Researchers did not assign a comparable group of participants to chemotherapy alone within this analysis.
That means historical survival figures and response rates for other treatments cannot demonstrate how much of the observed benefit came from adding daraxonrasib. Differences in patient selection, follow-up and measurement may also affect comparisons.
The study was sponsored by the manufacturer, Revolution Medicines. The conference’s account explicitly cautioned that the results need confirmation in a large randomized trial.
There were adverse effects, including rash, diarrhea, fatigue and chemotherapy-related reductions in blood-cell counts. Investigators reported that around 5% of patients discontinued treatment because of effects attributed to daraxonrasib. Larger studies will be needed to characterize the benefit-risk balance of this combination more precisely.
For a closer explanation of the FDA’s documented safety warnings, and why they cannot be directly applied to the newer combination trial, read Daraxonrasib side effects: FDA label versus trial findings.
Is daraxonrasib already FDA approved?
Yes, but for a different clinical situation. On August 26, 2026, the US Food and Drug Administration approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who had received at least one earlier systemic treatment or were unsuitable for multiagent systemic therapy.
That US decision was based on the separate randomized RASolute 302 trial, involving 500 previously treated patients. The FDA reported median overall survival of 13.2 months with daraxonrasib versus 6.7 months with the comparison chemotherapy in the overall study population.
The European Commission also approved Rasonque in November 2026 for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy. The country-by-country guide to daraxonrasib explains who falls within the US and EU indications and how UK patients can ask about trial access.
The newly reported first-line combination has not been established as an approved first-line regimen by these decisions. An FDA breakthrough therapy designation granted to the combination in September signals an expedited development pathway, rather than marketing authorization for that use.
What happens in the phase 3 trial?
The ongoing RASolute 303 trial is intended to provide the decisive comparison in people who have not previously received systemic therapy for metastatic pancreatic cancer.
It is evaluating daraxonrasib alone, daraxonrasib alongside gemcitabine and nab-paclitaxel, and chemotherapy alone. Random assignment should help establish whether the added treatment improves survival and other outcomes, and at what cost in adverse effects.
Until those results are available, the distinction between encouraging tumor shrinkage and proven additional survival benefit remains central.
What do the November results mean for patients?
The latest data suggest that targeting RAS while giving chemotherapy may become an important option for newly treated metastatic pancreatic cancer. They do not establish a cure, and they do not independently prove that the combination outperforms chemotherapy.
For patients discussing treatment, the immediate questions are which approved indication applies to their circumstances and whether participation in a relevant clinical trial is appropriate. Individual decisions require an oncology team’s assessment of prior treatment, overall health and the tumor’s characteristics.